Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Cancer Immunology, Immunotherapy · Published 2022-12-01 · Available online 21 May 2022 · Journal article · DOI 10.1007/s00262-022-03191-8 · PMID: 35596791 · PMC · Cited by 35 (Crossref)

Authors (14)

V. Moreno, E. Calvo, M. R. Middleton, F. Barlesi, C. Gaudy-Marqueste, A. Italiano, E. Romano, A. Marabelle, E. Chartash, K. Dobrenkov, H. Zhou, E. C. Connors, Y. Zhang, M. Wermke

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

71

Issue

12

Pages

2985-2998

Year

2022

Citation

Moreno, V., Calvo, E., Middleton, M., et al. (2022). Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-022-03191-8

Related articles

• Lactate and lactylation in tumor immunity · Frontiers of Medicine · 2025 · Cites or is cited by this article
• Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy · Molecular Imaging and Biology · 2026 · Cites or is cited by this article
• The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion · Tumour Virus Research · 2022 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

35